| Document Date: 2012-06-18 21:28:46
Open Document File Size: 38,78 KBShare Result on Facebook
Company Novartis Group / PR Newswire / Novartis AG / PR Newswire Association LLC / Novartis Oncology / United Business Media / / Country Germany / United States / / Event FDA Phase / / Facility University Marburg / Depot Controls Tumor Growth / / MedicalCondition Rare Gastrointestinal Tumors / Tumor / abdominal pain / adenomas / control tumor / Tumors / flushing / disease / carcinoid tumors / pituitary adenoma / acromegaly / neuroendocrine tumors / nausea / severe diarrhea / neuroendocrine tumor / fewer liver metastases / fever / vomiting / fatigue / diarrhea / metastatic neuroendocrine MIDgut tumors / constipation / metastatic neuroendocrine tumors / gallstones / / MedicalTreatment surgery / / Organization World Health Organization / FDA / US Securities and Exchange Commission / American Society of Clinical Oncology / / Person Rudolf Arnold / David Epstein / / Position PROMID Lead Investigator / President & CEO / / Product Sandostatin LAR / glucagon / octreotide acetate / RAD001 / / ProvinceOrState New Jersey / / URL www.us.sandostatin.com / http /
SocialTag |
New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors